Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 336

1.

R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.

Tomita N, Takasaki H, Miyashita K, Fujisawa S, Ogusa E, Matsuura S, Kishimoto K, Numata A, Fujita A, Ohshima R, Kuwabara H, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Fujimaki K, Taguchi J, Sakai R, Ishigatsubo Y.

Br J Haematol. 2013 May;161(3):383-8. doi: 10.1111/bjh.12281.

PMID:
23432318
2.

Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.

Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):569-77. doi: 10.1016/j.ijrobp.2013.02.007.

PMID:
23540349
3.

Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.

Kwon J, Kim IH, Kim BH, Kim TM, Heo DS.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):91-8. doi: 10.1016/j.ijrobp.2014.12.042.

PMID:
25721091
4.

Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.

Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS.

J Clin Oncol. 2010 Sep 20;28(27):4170-6. doi: 10.1200/JCO.2009.27.3441.

PMID:
20713859
5.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group..

Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2.

PMID:
21940214
6.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.

Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X.

7.

Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.

Meguro A, Ozaki K, Sato K, Oh I, Fujiwara S, Hosonuma R, Sasazaki M, Kikuchi Y, Hirata Y, Yamamoto C, Uesawa M, Kobayashi H, Matsu H, Okabe H, Uehara E, Nishikawa A, Tatara R, Hatano K, Yamamoto C, Matsuyama T, Toshima M, Ueda M, Ohmine K, Suzuki T, Mori M, Nagai T, Muroi K, Ozawa K.

Leuk Lymphoma. 2012 Jan;53(1):43-9. doi: 10.3109/10428194.2011.600486.

PMID:
21864040
8.

Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.

Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsirigotis P, Kyrtsonis MC, Kotsianidis I, Kalpadakis C, Dimopoulos MA, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP.

Hematol Oncol. 2013 Mar;31(1):10-7. doi: 10.1002/hon.2012.

PMID:
22610484
9.

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.

Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M.

Leuk Lymphoma. 2012 Apr;53(4):581-8. doi: 10.3109/10428194.2011.621565.

PMID:
21895543
10.

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.

Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0.

PMID:
22160255
11.

Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.

Chae YS, Shin H, Sohn SK, Lee SJ, Moon JH, Kang BW, Kim JG, Yang DH, Lee JJ, Park TI.

Leuk Lymphoma. 2012 Sep;53(9):1757-63. doi: 10.3109/10428194.2012.670231.

PMID:
22372848
12.

Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.

Hasselblom S, Stenson M, Werlenius O, Sender M, Lewerin C, Hansson U, Nilsson-Ehle H, Andersson PO.

Leuk Lymphoma. 2012 Mar;53(3):394-9. doi: 10.3109/10428194.2011.616612.

PMID:
21864039
13.

Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.

Seker M, Bilici A, Ustaalioglu BO, Yilmaz B, Ozturk B, Ünal A, Dane F, Ozdemir NY, Elkiran ET, Kalender ME, Gumus M, Benekli M.

Arch Gynecol Obstet. 2011 Aug;284(2):405-9. doi: 10.1007/s00404-010-1683-y.

PMID:
20872226
14.

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.

J Clin Oncol. 2006 Jul 1;24(19):3121-7.

PMID:
16754935
15.

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.

Tai WM, Quah D, Yap SP, Tan SH, Tang T, Tay KW, Koo YX, Tao M, Quek R, Lim ST.

Leuk Lymphoma. 2011 Apr;52(4):604-12. doi: 10.3109/10428194.2010.550073.

PMID:
21261504
16.

High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.

Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.

Eur J Haematol. 2012 Jun;88(6):510-7. doi: 10.1111/j.1600-0609.2012.01778.x.

PMID:
22413767
17.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Lancet Oncol. 2013 May;14(6):525-33. doi: 10.1016/S1470-2045(13)70122-0.

PMID:
23578722
18.

Survival of patients with transformed lymphoma in the rituximab era.

Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, Zhang L, Buckstein R.

Ann Hematol. 2014 Jun;93(6):1007-14. doi: 10.1007/s00277-013-1991-y.

PMID:
24414374
19.

[Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].

Ueda K, Yokoyama M, Asai H, Koudaira M, Yamada S, Katsube A, Mishima Y, Sakajiri S, Takeuchi K, Saotome T, Terui Y, Takahashi S, Hatake K.

Gan To Kagaku Ryoho. 2010 May;37(5):853-7. Japanese.

PMID:
20495315
20.

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.

Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.

Clin Lymphoma Myeloma. 2009 Oct;9(5):381-5. doi: 10.3816/CLM.2009.n.074.

PMID:
19858058

Supplemental Content

Support Center